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Although tau is mainly known as an axonal microtubule-associated protein, many studies indicate that it is not restricted to this 
subcellular compartment. Assessing tau’s subcellular distribution, however, is not trivial as is evident from transgenic mouse 
studies. When human tau is over-expressed, it can be immunohistochemically localized to axons and the somatodendritic do-
main, modeling what is found in neurodegenerative diseases such as Alzheimer’s disease. Yet, in wild-type mice, despite its 
abundance, tau is difficult to visualize even in the axon. It is even more challenging to detect this protein in the nucleus, where 
tau has been proposed to protect DNA from damage. To establish a framework for future studies into tau’s nuclear functions, 
we compared several methods to visualize endogenous nuclear tau in cell lines and mouse brain. While depending on the fixa-
tion and permeabilization protocol, we were able to detect nuclear tau in SH-SY5Y human neuroblastoma cells, we failed to do 
so in N2a murine neuroblastoma cells. As a second method we used subcellular fractionation of mouse tissue and found that in 
the nucleus tau is mainly present in a hypophosphorylated form. When either full-length or truncated human tau was expressed, 
both accumulated in the cytoplasm, but were also found in the nuclear fraction. Because subcellular fractionation methods have 
their limitations, we finally isolated nuclei to probe for nuclear tau and found that the nuclei were free of cytoplasmic contam-
ination. Together our analysis identifies several protocols for detecting tau in the nucleus where it is found in a less phosphory- 
lated form. 
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A major interest in the protein tau stems from the fact that it 
forms insoluble aggregates in many neurodegenerative dis-
eases including Alzheimer’s disease (AD) [1]. Tau belongs 
to the family of microtubule-associated proteins (MAPs), 
with tau being the prototypical axonal and MAP2 the pro-
totypical dendritic family member [2]. MAPs have a central 
role in neuronal integrity [3]. While tau has a major func-
tion in the axon, early on it was recognized that this protein 
has also important physiological functions in other com-
partments, such as the dendrite, where low concentrations of 
tau facilitate the targeting of the tyrosine-directed kinase 
Fyn to the dendritic spines [4]. The dendrite is not the only 
‘non-canonical’ subcellular compartment to which tau has 
been localized; in fact, studies to localize tau to cell-types 
other than the neuron and subcellular compartments other 
than the axon date back to the early 1990s when the 
dephosphorylation-dependent anti-tau antibody Tau-1 was 
used to visualize nuclear tau in some but not all neuroblas-
toma cell lines investigated [5].  
Whether there are also changes to nuclear tau in AD is 
unknown, but interestingly, RNA splicing alterations have 
been identified, suggesting that the nucleus needs to be fac-
tored in when pathogenesis of AD is studied [6]. When an-
alyzing nuclear tau, human cell lines (JC, CG, LA-N-5,  
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HeLa, and SH-SY5Y) consistently showed nucleolar Tau as 
detected with the Tau-1 antibody, while a rodent neuroblas-
toma cell line (N2a) consistently failed to do so [5,7,8]. 
Two human cell lines (JC and CG) were further analyzed by 
subcellular fractionation followed by formic acid (FA) ex-
traction to enrich for insoluble proteins. One cell line (CG) 
failed to reveal cytoplasmic tau, and tau was only observed 
in the nuclear FA fraction, while a second cell line (JC) re-
vealed tau in both the soluble and FA fraction [5]. Cyto-
plasmic tau was shown not to localize to microtubules [8]. 
Together this was interpreted such as that tau exists in the 
nucleus in a less soluble form. Subsequently, using human 
brain tissue, isolated nuclei were used to demonstrate the 
insolubility of nuclear tau [9]. It was argued that nuclear tau 
is highly insoluble as much as tau is in the paired helical 
filaments (PHFs) that are found in the tau tangles in AD 
brain. Furthermore, it was suggested at the time that in AD, 
tau would even form PHFs in nuclei. It was speculated that 
the nucleus might contain factors that are capable of induc-
ing PHF formation, and when these nuclear PHFs are re-
leased into the cytoplasm that they would act as a catalyzer 
of tau aggregation and subsequent neurodegeneration. A 
nuclear role for tau was extended to human non-neuronal 
cells, demonstrating shared structural and functional fea-
tures of nuclear and cytoplasmic tau [10]. Tau is a phospho- 
protein, with hyperphosphorylation causing its aggregation 
[11]. It is therefore not unreasonable to assume that subcel-
lular targeting in general depends on phosphorylation. Sim-
ilar to plasma membrane-localized tau being less phosphor-
ylated [4,12], there is evidence that oxidative and heat stress 
causes tau to enter the nucleus in a dephosphorylated form 
[13]. Whether under physiological conditions the phosphor-
ylation status of nuclear tau differs from that of non-nuclear 
tau is not known. 
In analyzing tau distribution, in particular its localization 
to the nucleus, a review of the literature and our own expe-
rience show that tau is not easily detected in this compart-
ment. In general, tau is difficult to visualize by immuno-
histochemistry in mouse brain unless the protein is 
over-expressed by transgenic approaches. While this reveals 
axonal and somatodendritic localization, it is difficult on 
non-transgenic sections to even detect axonally localized 
tau, and it is even more challenging to visualize nuclear tau. 
To visualize the latter, the dephosphorylation-dependent 
anti-tau antibody Tau-1 has been widely used, while most 
other antibodies failed to detect nuclear tau, possibly re-
flecting the phosphorylation status of tau in the nucleus. 
Different experimental systems, protocols and antibodies 
have been used in the past, providing conflicting results.  
The purpose of our study was therefore to establish a set 
of robust methods to detect and visualize nuclear tau, in-
cluding tau knockout samples as controls. Robust methods 
of visualizing nuclear tau are a prerequisite in order to ob-
tain a better understanding of the role nuclear tau has in 
neurons, and to get a handle on what regulates the allocation 
of tau to different subcellular compartments. Therefore, we 
validated a range of detection methods in cell culture and in 
vivo. Together our study shows that tau can be detected in 
the nucleus in human SH-SY5Y but not murine N2a neuro-
blastoma cells, and that detection depends on a specific 
protocol. Fractionation revealed that tau in the nucleus is 
less phosphorylated than in the cytoplasm. Finally, we 
found that the isolation of intact nuclei is an elegant method 
to visualize and analyze nuclear tau. 
1  Materials and methods 
1.1  Cell culture and immunohistochemistry 
SH-SY5Y human and N2a murine neuroblastoma cells were 
cultured in DMEM medium (Life Technologies, Melbourne, 
VIC, Australia) supplemented with 10% FBS (Hyclone). 
Cells were plated at 1×105 mL1 into 12 well plates that 
were plated with poly-D-lysine-coated coverslips. After  
24 h, the medium was replaced by DMEM/1% FBS. After 
24 h of serum deprivation, the vast majority of cells were in 
G1 stage. The cells were fixed and permeabilized according 
to previously established procedures (Table 1), followed by 
incubation with the dephosphorylation-dependent anti-tau 
antibody Tau-1 (Millipore, Billerica, MA, USA; 1:200) and 
the phosphorylation-independent anti-Tau antibody Dako 
Tau (Dako, Glostrup, Denmark; 1:200). Secondary antibod-
ies were goat anti-rabbit and goat anti-mouse conjugated to 
Alexa Fluor 488 and 568, respectively (Life Technologies, 
USA). DNA was counterstained with DAPI (Sigma, St 
Louis, MO, USA). Images were taken with a Zeiss LSM 
510 inverted confocal microscope. 
Specifically, the following six methods were validated 
(Table 1): 
Method I [5].  After washing with PBS, the cells were 
fixed with 3% formaldehyde for 30 min at 24°C, then per-
meabilized with 0.5% Triton X-100 in PBS (PBST) for    
5 min, rinsed twice in PBS, reduced in 0.5g mL1 NaBH4 
in PBS for 4 min, and blocked with 1% BSA in PBS for  
10 min. Incubation with primary antibodies was done at 4°C 
in 1% BSA overnight. Incubation with secondary antibodies 
was done at 37°C for 30 min in PBS. Preparations were 
counterstained with DAPI before mounting with mounting 
medium (Dako). 
Method II [10].  After washing with PBS, the cells were 
fixed with pre-cooled methanol at 20°C for 15 min. After 
rinsing with PBS three times, the cells were incubated with 
primary antibodies in 2% BSA. After washing with PBS, 
secondary antibodies were applied in 2% BSA. 
Method III [14].  The cells were first fixed with 1% 
PFA for 20 min, and then with methanol for 10 min. The 
cells were permeabilized with 0.2% PBST, before blocking 
with 5% BSA. Antibodies were used in the same way as for 
Method I except that 5% instead of 1% BSA was used for 
the reaction buffer. 
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Table 1  Methods used previously to visualize nuclear tau protein in various experimental systemsa) 










































       
III 
 







































































a) The methods are numbered consecutively (IVI), based on the publication year of the respective study. Abbreviations used: PFA, paraformaldehyde; 
PBST, PBS, Triton-X-100; BSA, bovine serum albumin; NGS, normal goat serum; N.D., not done; Tau3R, antibody specific for 3R tau; phospho-T181, 
phospho-S396; see opposite order in IV. Note that for method IV, cells were heat-shocked, while for method V, they were formaldehyde-treated. 
Method IV [13].  After washing with PBS, the cells 
were first permeabilized with 0.2% PBST for 5 min (Sultan 
and colleagues had permeabilized for 10 min, but that 
seemed too harsh to us as under these conditions most cells 
came off), then the cells were fixed in cold methanol for 10 
min at 20°C. The cells were washed with PBS before 
blocking with 2% BSA. Antibodies were used as for Method 
I except that 2% BSA was used for the reaction buffer. 
Method V [15].  After washing with PBS, the cells were 
fixed with 4% PFA, followed by permeabilization with 
0.1% PBST. The cells were blocked with 5% NGS (normal 
goat serum) before the antibodies were applied as described 
in Method I, with 5% NGS being used for the reaction  
buffer. 
Method VI [16].  After washing with PBS, the cells 
were fixed with 4% PFA, then blocked directly with 3% 
BSA and 0.1% NGS containing 0.1% Triton X-100 in PBS. 
Then the antibodies were used in the same way as for 
Method I except that 3% BSA and 0.1% NGS containing 
0.1% Triton X-100 in PBS was used for the reaction buffer. 
1.2  Animal models and ethics 
C57BL/6 mice, tau knockout mice [20], pR5 mice that ex-
press human P301L mutant full-length tau [21], and ∆Tau74 
mice that express a truncated form of wild-type human tau 
that lacks the microtubule-binding domain [4], were all 
supplied by UQ Biological Resources. The animal experi-
mentation was approved by the Animal Ethics Committees 
of the University of Queensland (approval number QBI/ 
027/12/NHMRC). 
1.3  Subcellular fractionation, sequential extraction and 
Western blot analysis 
Brain tissue from 3-month-old male mice was fractionated 
into cytoplasmic and nuclear fractions [17], followed by 
dephosphorylation of the extracts with λ protein phospha-
tase (New England Biolabs, Hitchin, UK) according to the 
manufacturer’s instructions. To obtain fractions of increas-
ing insolubility, a sequential extraction was performed with 
the nuclear fraction. High salt reassembly buffer (RAB) (0.1 
mol L1 Mes, 1 mmol L1 EGTA, 0.5 mmol L1 MgSO4, 
0.75 mol L1 NaCl, 0.02 mol L1 NaF, 1 mmol L1 PMSF, 
0.1% complete protease inhibitor (Roche), pH 7.0) was used 
to generate the RAB-soluble fractions. The resulting pellets 
were extracted with radioimmunoprecipitation assay (RIPA) 
buffer (50 mmol L1 Tris, 150 mmol L1 NaCl, 1% Nonidet 
P-40, 5 mmol L1 EDTA, 0.5% sodium deoxycholate, 0.1% 
SDS, pH 8.0) and centrifuged to generate RIPA-soluble 
samples. Finally, the RIPA-insoluble pellets were re-   
extracted with 70% formic acid (FA) to recover the most 
insoluble cytoskeletal aggregates. This was followed by 
dephosphorylation with λ protein phosphatase. Western 
blotting was performed as described previously [18]. To 
determine the phosphorylation of tau [19], the dephosphor-
ylation step was omitted and brain extracts were immuno- 
blotted with antibodies AT8 (specific for pS202/pT205 of 
tau, 1:2000; Thermo Scientific, USA), AT180 (specific for 
pT231/pS235, 1:2000; Thermo Scientific), AT270 (specific 
for pT181, 1:2000; Thermo Scientific), and 12E8 (specific 
for pS262/pS356, kind gift of Dr. Peter Seubert, Neotope 
Inc., Palo Alto, CA, USA), followed by incubation with 
IRDye fluorescent secondary antibodies (LI-COR, Lincoln, 
NE, USA; 1:10000) and detection using the Infrared Imag-
ing system (LI-COR). Quantification was done with the 
Odyssey Application Software Version 3.0, and for statisti-
cal analysis, Prism 6 was used for plotting and statistics. 
The data were expressed as mean±standard deviation (SD). 
A two-tailed t-test was carried out to determine the differ-
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ence of tau phosphorylation between nuclear and cytoplas-
mic fractions. **, P<0.01; ***, P<0.001. 
1.4  Isolation of nuclei and confocal analysis 
Nuclei were isolated from brains of 3-month-old C57BL/6 
mice and tau knockout mice [20], using a nuclei isolation 
kit (Sigma, St Louis, MO, USA; NUC101-1KT). The nuclei 
were first identified with DAPI staining using a fluorescent 
microscope (Olympus CKX41, Japan). A suspension of 1–2 
million/mL nuclei was generated and cyto-spun with a 
Cellspin I centrifuge (THARMAC, Germany) onto glass 
slides. Cytospot used 100 μL per slide, centrifuging at 2000 
r min1 for 2 min. Once the slides were dry, they were kept 
in the fridge until further use. Immunostaining was done as 
previously reported [9,15], except that the nuclei were per-
meabilized with 0.2% PBST after fixation. Nuclei were 
stained for GAPDH (Millipore; Cat. ABS16, 1:200), tubulin 
(Sigma; Cat. T6074, 1:200), Dako Tau and Lamin B 
(Abcam; Cat. ab16048, 1:200). The same secondary anti-
bodies were used as for immunocytochemistry. Alterna-
tively, nuclei can also be incubated directly with the anti-
bodies in Eppendorf tubes, centrifuged at 250×g for 5 min, 
washed, and then evenly spread onto glass slides for 
mounting. This method better preserves the nuclear mor-
phology than cytospinning on slides but consumes many 
more nuclei. Images were taken with a Zeiss LSM 510 in-
verted confocal microscope. Z-stacks were obtained to 
demonstrate the intactness of the nuclei using either Lamin 
B staining or staining for tau and Lamin B. The latter was 
further reconstructed with Imaris surpass and spot modules 
and colocalization of tau and DNA was calculated with the 
coloc module (Imaris, Bitplane, St. Paul, MN, USA). 
2  Results 
2.1  Nuclear staining for tau is cell type- and fixa-
tion-dependent 
In order to obtain a method that would allow the visualiza-
tion of nuclear tau in tissue culture cells, we validated sev-
eral protocols that had previously demonstrated endogenous 
tau in the nucleus (Table 1). Several of these protocols had 
used the antibody Tau-1 that detects tau when not phos-
phorylated at the AT8 phospho-epitope Ser202/Thr205. 
Two of the methods (IV and V) subjected the cells to either 
heat-shock or formaldehyde treatment which caused tau to 
localize to the nucleus [13,15]. For our comparative analysis, 
we used undifferentiated human SH-SY5Y and murine N2a 
cells. Both cell lines are widely used in the field. SH-SY5Y 
cells can be neuronally differentiated, using retinoic acid 
[22]. When kept undifferentiated, they differ from fibro-
blasts by having a bipolar morphology, as is also found for 
N2a cells [15,23]. We synchronized the cells by se-
rum-deprivation, followed by processing according to the 
six protocols IVI, using Tau-1, Dako Tau (a phosphoryla-
tion-independent pan-neuronal anti-tau antibody) and the 
nuclear marker DAPI (in blue) for visualization (Figures 1 
and 2). The six protocols vary with regards to fixation, per-
meabilization, and blocking buffer used (Table 1). In 
SH-SY5Y cells (Figure 1), for all six protocols, Tau-1 
staining was confined to the nucleus. Reactivity with Tau-1 
was confined to the nucleus, and Dako Tau reactivity was 
absent at all when protocol I was used. Protocol II revealed 
a strong cytoplasmic and a punctate non-overlapping stain-
ing with Tau-1 for the nucleus. Protocol III revealed a very 
weak punctate, diffuse staining for Dako Tau in the nucleus 
and cytoplasm, and nuclear staining with Tau-1. Protocol IV 
revealed a punctate Dako Tau staining. Note that because of 
the reverse order of fixation and permeabilization, the 
bright-field images for IV look different compared with the 
other five methods. Of all protocols, protocols V and VI 
yielded the strongest overall staining, with pronounced focal 
staining for Tau-1 in the nucleus, and a strong staining for 
Dako Tau in the cytoplasm. Different from SH-SY5Y cells, 
N2a cells failed to reveal nuclear tau staining, both with 
Dako Tau and Tau-1 (Figure 2). Dako Tau revealed a strong 
cytoplasmic staining for all protocols but IV that revealed a 
subtle punctate staining. Interestingly, Tau-1 led to strong, 
diffuse cytoplasmic staining with protocols II, III, V and VI. 
There is evidence for very slight nuclear Dako Tau staining 
when using methods II and V. While we have not applied a 
systematic approach to test all combinations of fixation, 
permeabilization, and blocking buffer, for practical purpos-
es protocol V worked best in visualizing nuclear and cyto-
plasmic tau in human SH-SY5Y cells. The data also show 
that N2a cells fail to present with nuclear tau within the 
limit of our detection method.  
2.2  In mouse brain both endogenous and transgenic 
tau are in the nuclear fraction 
We have previously analyzed the distribution and localiza-
tion of the three major murine tau isoforms in the adult 
brain, 0N4R, 1N4R and 2N4R [16]. This revealed that the 
brain is the only organ to express tau at significant levels, 
with 0N4R being the predominant isoform in the 2-month- 
old adult. Subcellular fractionation of the brain showed that 
the 1N isoform is over-represented in the soluble nuclear 
fraction. This is in agreement with the immunohistochemi-
cal analysis as the 1N isoform strongly localizes to the neu-
ronal nucleus, although it is also found in cell bodies and 
dendrites, but not axons. The 0N isoform was mainly found 
in cell bodies and axons, whereas nuclei and dendrites were 
only slightly stained with the 0N antibody. The 2N isoform 
was found to be highly expressed in axons and in cell bod-
ies, with a detectable expression in dendrites and a very 
slight expression in nuclei. The 2N isoform that was unde- 
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Figure 1  Visualizing endogenous nuclear Tau by immunofluorescence in SH-SY5Y cells. SH-SY5Y human neuroblastoma cells were synchronized by 
serum deprivation and then processed using the fixation, permeabilization and blocking conditions listed in Table 1, employing antibodies Tau-1 (in red) and 
Dako Tau (green) as well as the nuclear marker DAPI (blue) for detection. Note that because of the reverse order of fixation and permeabilization, the 
bright-field images obtained with protocol IV look different from those obtained with the other five methods. 
tectable at P0, in adult brain was mainly found localized to 
cell bodies and dendrites [16]. 
Here, we determined which isoforms are nuclear by per-
forming a crude fractionation of adult wild-type (C57BL/6) 
mouse brain, obtaining a nuclear (N), cytoplasmic (C) and 
total (T) fraction from three mice each. Our analysis con-
firmed previous findings that all three murine tau isoforms 
are also found in the nuclear fraction (Figure 3A). Our pre-
vious isoform study only analyzed RAB fractions, using 
dephosphorylated tau [16]. To determine the solubility of 
nuclear tau, here, we performed a sequential extraction that 
allowed us to enrich for increasingly insoluble proteins. We 
found all three isoforms in the nuclear RAB and in the less 
soluble RIPA fraction, but not the FA fraction (Figure 3B). 
This indicates that in the nucleus tau exists in different 
states of solubility. We next determined whether transgen-
ically expressed human tau, which has been shown to be 
enriched in the somatodendritic domain [24], would also be 
found in the nuclear fraction. As a negative control for an-
tibody specificity we used tau knockout mice [20]. We ana-
lyzed two tau transgenic mouse strains; pR5 mice that ex-
press human P301L mutant full-length tau [21], and ∆Tau74 
mice that express a truncated form of wild-type human tau 
that lacks the microtubule-binding domain [4]. We found 
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Figure 2  Visualizing endogenous nuclear Tau by immunofluorescence in N2a cells. N2a murine neuroblastoma cells were synchronized by serum depriva-
tion and then processed using the methods listed in Table 1, employing antibodies Tau-1 (in red) and Dako Tau (green) as well as DAPI (blue) for detection. 
Different from SH-SY5Y cells, N2a cells virtually do not express tau in nuclei. Note: Because of the reverse order of fixation and permeabilization, the 
bright-field images obtained with protocol IV look different from those obtained with the other five methods.  
that both full-length and truncated human tau not only ac-
cumulate in the cytoplasmic but also in the nuclear fraction 
(Figure 3C).  
2.3  Subcellular fractionation reveals dephosphorylated 
tau in the nucleus 
Tau is a phospho-protein under physiological conditions. In 
the adult brain, there are two to three moles of phosphate 
per mole of tau [11], and this ratio is increased in the de-
veloping brain [25]. Because tau is mainly localized to the 
cytoplasm, we set out to determine whether tau would be 
phosphorylated to a similar degree in the nucleus as has 
been found for the cytoplasm. We therefore analyzed the 
nuclear and cytoplasmic fractions of 3-month-old C57BL/6 
mice using the phospho-tau antibodies AT8, AT180, AT270 
and 12E8, and found that nuclear tau is largely dephosphor-
ylated (Figure 4A). We quantified the degree of hypophos-
phorylation of nuclear tau by determining the ratio of phos-
phorylated tau to total tau levels in the respective fractions 
(Figure 4B). Together this shows that in adult wild-type 
mouse brain, tau is strongly dephosphorylated in the nucle-
us compared to the cytoplasm. Whether this applies to all 
phospho-epitopes of tau remains to be determined.
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Figure 3  Western blot analysis of subcellular fractionations of brain tissue detects nuclear tau. A, Subcellular fractionation of three wild-type mouse brains 
into nuclear (N) and cytoplasmic (C) fraction, followed by dephosphorylation. T, total lysate. Tubulin was used as cytoplasmic and histone H3 as nuclear 
marker throughout. B, Differential extraction of the nuclear fraction into increasingly insoluble fractions reveals all three tau isoforms in the RAB (high salt 
reassembly buffer) fraction N1, and the RIPA (radioimmunoprecipitation assay buffer) fraction N2, but not the FA (formic acid) fraction N3. C, Fractiona-
tion of brains from human P301L mutant tau transgenic pR5 mice, using Tau KO (knockout) mice as controls, reveals transgenic tau in nuclear fraction. D, 
Analysis of brain fractions from ∆Tau74 mice that over-express the projection domain of human tau (and lack the microtubule-binding domain) reveals 
∆Tau in nuclear fraction.  
2.4  Tau can be detected in nuclei isolated from mouse 
brain 
Because there is the possibility that, due to their biochemi-
cal properties, cytoplasmic proteins might contaminate the 
nuclear fraction, we used an alternative method where this 
potentially confounding factor is ruled out. We therefore 
isolated intact nuclei from 3-month-old C57BL/6 wild-type 
and tau knockout brains, followed by staining with tubulin 
and GAPDH (representing cytoplasmic markers that should 
be absent), DAPI (nuclear marker), tau, and Lamin B (nu-
clear envelope marker) (Figure 5). We firstly found for tu-
bulin, GAPDH and DAPI, that the protocol isolated nuclei 
that were virtually free of any contamination of cytoplasmic 
markers (Figure 5A). We next performed Z-stacking to 
demonstrate that the nuclei were intact, as demonstrated by 
staining with Lamin B and DAPI (Figure 5B). As was evi-
dent from the different layers, the Lamin B-labelled nuclear 
envelope was intact. The staining further revealed that the 
nuclei were obtained without contamination of cytoplasmic 
proteins. To reveal nuclear tau staining in wild-type nuclei, 
we used DAPI and tau staining (Figure 5C). Tau was 
stained in many but not all nuclei from mouse brain, be-
cause not all cell-types in brain are neurons that express tau 
at substantial levels. As a negative control, we included 
nuclei from tau knockout brains. Finally, we obtained 3D 
images reconstructed with Imaris that demonstrated a seg- 
regation of DAPI (heterochromatin DNA) and tau staining 
in nuclei of wild-type mice (Figure 5D). The Imaris work-
station was used to reconstruct three-dimensional images to 
show the relative position of tau and DNA. The Pearson 
coefficient was calculated, demonstrating that tau and DAPI 
are most likely not co-localized. However, this does not 
imply that tau does not interact with DNA. Because tau is 
localized to the less DAPI-reactive euchromatin, it can still 
interact with DNA and confer protection from stress. Future 
studies will investigate whether nuclear tau levels and/or 
their distribution differ depending on the neuronal cell-type. 
3  Discussion 
There is an increasing interest in non-canonical functions of 
tau, a protein traditionally allocated to the axon where it 
binds to and stabilizes microtubules [26]. The new interest 
extends to the nucleus where tau is believed to have an im-
portant scaffolding function [13,27]. Because, in the past, 
data on nuclear tau expression have been inconsistent, in 
part because of different fixation methods and experimental 
systems, we validated three principal methods: immunocy-
tochemical staining of human and murine neuroblastoma 
cell lines testing six protocols, subcellular fractionation of 
wild-type and human tau transgenic mouse brain, and isola-
tion of nuclei from mouse brain. 
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Figure 4  Hypophosphorylation of nuclear tau. A, Analysis of Tau phos-
pho-epitopes AT8, AT180, AT270, and 12E8. B, Quantification of the 
relative phosphorylation levels in the nucleus, normalizing for total tau. 
Nuclear (N), cytoplasmic (C) fraction and total lysate (T). Tubulin was 
used as cytoplasmic and histone H3 as nuclear marker. Data was expressed 
as mean±SD. **, P<0.01; ***, P<0.001. 
All three methods revealed nuclear tau. Applying the first 
approach, we found that N2a murine neuroblastoma cells 
did not contain detectable levels of tau in the nucleus, 
whereas SH-SY5Y neuroblastoma cells that are human- 
derived did. For SH-SY5Y cells, not all protocols enabled 
us to visualize nuclear tau equally well. Rather, we found 
that fixing the cells with 4% PFA, permeabilizing them with 
0.1% PBST and blocking them with 5% NGS yielded the 
best results, with Dako Tau detecting both cytoplasmic and 
to some degree nuclear tau, and Tau-1 exclusively detecting 
nuclear tau, with a pattern that did not overlap with Dako 
Tau. Our data confirm previous findings that indicated dif-
ferences in nuclear tau localization between human and mu-
rine cell-types [5]. They further suggest that tau exists in 
different conformations and that the different epitopes are 
accessible to the respective antibodies in a compart-
ment-specific manner. In other words, the data suggest that 
while tau is tightly bound to microtubules in axons, in the 
nucleus it is also tightly bound, although to different pro-
teins, making tau less accessible to antibodies. This notion 
is supported by the finding that in formaldehyde-treated 
N2a cells, tau can be detected in the nucleus only with some 
of the tested tau antibodies [15]. Likewise, in heat 
shock-treated cortical primary neurons, tau could be visual-
ized in nuclei using either the 3R tau-specific antibody 
Tau3R or with Tau-1 [13]. 
Being nuclearly localized, tau was found to be dephos- 
phorylated whereas work by others implies that thermal and 
other forms of stress cause the opposite, i.e., hyperphos-
phorylation of tau [15,28]. We found under unstressed con-
ditions that tau is dephosphorylated in the nucleus, reminis-
cent of what has been reported for both membrane-    
associated and secreted tau [29]. 
Crude subcellular fractionation, our second method, 
showed that all three major adult tau isoforms (0N4R, 1N4R 
and 2N4R) are present in both the cytoplasmic and nuclear 
fraction, and that a sequential extraction using RAB, RIPA 
and FA identifies nuclear tau both in the soluble RAB and 
in the insoluble (or at least less soluble) RIPA fraction. We 
did not find tau in the highly insoluble FA fraction. These 
findings support our previous findings by subcellular frac-
tionation that the 1N4R isoform of tau is under-represented 
in the chromatin-associated and cytoskeletal fraction and 
over-represented in the soluble nuclear fraction [16]. Sub-
cellular fractionation is to some degree a crude method and 
proteins can purify in particular fractions without neces-
sarily being in the corresponding subcellular compartment, 
simply because their biochemical properties caused them to 
co-purify with that particular fraction. Here, a novel method 
might help that performs a proteomic mapping in living 
cells using spatially restricted enzymatic mapping, with 
ascorbate peroxidase (APEX) being the tag [30]. 
As a third method we directly isolated nuclei. Lamin B 
staining and 3D reconstruction revealed that the nuclei we 
had isolated were intact. In our view, this is the most con-
vincing evidence for tau being localized in nuclei, especial-
ly as we have been using tau knockout nuclei as a control 
that failed to demonstrate nuclear tau. 
What are the functions of nuclear tau? Nuclear tau has 
been localized to nucleoli and to the nucleolar organizing 
regions (NORs) where it may have a role in the synthesis 
and transcription of rRNA [5,31]. A putative role is also in 
nucleolar organization by binding to pericentromeric DNA 
[14]. The punctate pattern seen for Tau-1 in our immuno-
cytochemical study in SH-SY5Y cells is reminiscent of that 
of nucleoli although this has not been further investigated. 
In vitro studies further revealed that purified tau binds to 
AT-rich sequences in the minor groove of DNA [27]. Using 
an electrophoretic mobility shift assay (EMSA) it was 
shown that both the proline-rich domain and the microtu-
bule-binding domain contribute to the interaction of tau 
with DNA. Tau has further been shown to increase the 
melting temperature of DNA [32]. Finally, DNA was found  
430 Lu J, et al.   Sci China Life Sci   April (2014) Vol.57 No.4 
 
Figure 5  Tau can be detected in nuclei isolated from wild-type mouse brain, using tau knockout (KO) samples as negative control. A, Isolated nuclei 
(DAPI; blue) were tested with antibodies for tubulin and GAPDH revealing no contamination with cytoplasmic proteins. B, Z-stack imaging of wild-type 
and tau knockout nuclei showing that the nuclei are intact. Lamin B (green), DAPI (blue). C, Images showing nuclei stained with Dako Tau antibody (green). 
Top row, wild-type; bottom row, tau KO. D, 3D image reconstruction with Imaris surpass and spot modules, and colocalization calculation with coloc mod-
ule. Tau (green) distributes independently from DNA (blue). Lamin B (red). Pearson’s coefficient, 0.067. 
to be protected from free radical damage by tau [27]. In 
taking this a step further, work in primary neuronal cultures 
suggested that tau has a role in protecting DNA in the nu-
cleus from damage such as heat shock or oxidative stress 
[13]. This protective function was correlated with an in-
creased binding of tau to DNA via its AT-rich minor groove. 
Interestingly, when this interaction was inhibited with the 
antibiotic netropsin, the unbound tau did not stay in the nu-
clear fraction. Whether shuttling of tau into the nucleus re-
quires specific cargo proteins remains to be determined. Tau 
has also a role in the nucleo-cytoplasmic relocalization of 
nuclear proteins such as the splicing factor SFPQ; however, 
whether this relocalization is governed by nuclear tau re-
mains to be determined [33]. 
In conclusion, we have tested six protocols for the visu-
alization of nuclear tau in cultured cells of which several 
revealed prominent nuclear staining using antibody Tau-1 in 
SH-SY5Y cells. No nuclear tau was found in N2a cells cul-
tured under normal conditions. Crude fractionation of 
wild-type mouse brain reveals tau in the soluble RAB and to 
a lesser extent, the less soluble RIPA, but not the insoluble 
FA fraction. Tau in the nuclear fraction is hypophosphory-
lated compared with the cytoplasm. Finally, we present the 
isolation of nuclei as a viable method to both visualize nu-
clear tau and investigate its role in the nuclear architecture. 
Together, this insight will assist in dissecting the role of 
nuclear tau and in developing a tau-based therapy in AD 
[34,35]. 
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